Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Autor: Lorcan P McGarvey, Zhi Jin Xu, Vivek Iyer, James Krainson, James H. Hull, Mark H Gotfried, Jaclyn A Smith, David Muccino, Gary C Steven, Douglas McQuaid, David I. Bernstein, Gregory Daniel Brooks, David Elkayam, Wen-Chi Wu, Selwyn Spangenthal, Mandel R Sher, Jaclyn A. Smith, Yu-Ping Li, John J Condemi, Ellen R Sher, John R Holcomb, W. Carr, Gary N Gross, SM Parker, Gary D Berman, Ratko Djukanovic, Thomas B. Casale, Jason H Friesen, Krishna Sundar, Christopher E. Brightling, Michael Denenberg, Neil Ettinger, S S Birring, Faisal Alfonso Fakih, Bruce M Prenner, Lorcan McGarvey, Niran J Amar, Jonathan Corren, Tim Harrison, Shaila U Gogate, William W. Storms, Alyn H. Morice, Iftikhar Hussain, Leon S Greos, Anthony Montanaro, Anthony P. Ford, James S Good, Eric J Schenkel, Surinder S. Birring, Thomas R Murphy, Michael S Kaplan, William R Lumry, Jonathan Matz, Michael M. Kitt, Mandel Sher, Alan B Goldsobel, Ian D. Pavord

Publikováno v: Protocol 012 Investigators 2020, ' Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(19)30471-0

BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed8062bd34a8ad548083ad97ee59fbd
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html